In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic
prostate cancer and died of the disease; after the introduction of the serum PSA test …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

Purpose: Prostate specific antigen and free prostate specific antigen have limited specificity
to detect clinically significant, curable prostate cancer, leading to unnecessary biopsy, and …

Purpose: The Prostate Health Index (phi) is a new test combining total, free and [-2] proPSA
into a single score. It was recently approved by the FDA and is now commercially available …

Prostate cancer (PCa) is a widespread malignancy with global significance, which
substantially affects cancer-related mortality. Its spectrum varies widely, from slow …

Background The four-kallikrein panel and the Prostate Health Index (PHI) have been shown
to improve prediction of prostate cancer (PCa) compared with prostate-specific antigen …

Prostate cancer (PC) is one of the most common tumors and a leading cause of mortality
among men, resulting in~ 375 000 deaths annually worldwide. Various analytical methods …

BACKGROUND: Strategies to reduce prostate-specific antigen (PSA)–driven prostate
cancer (PCa) overdiagnosis and overtreatment seem to be necessary. OBJECTIVE: To test …

Purpose: We evaluated the ability of PHI to discriminate aggressive prostate cancer from
indolent or no cancer in a biopsy naïve population. Materials and Methods: Two …

Simple Summary In prostate cancer, overdiagnosis and overtreatment is a common problem
for clinicians. Accurate diagnosis and prognosis are essential to avoid unnecessary biopsy …